Two phase 3 trials of dupilumab versus placebo in atopic dermatitis EL Simpson, T Bieber, E Guttman-Yassky, LA Beck, A Blauvelt, MJ Cork, ... New England Journal of Medicine 375 (24), 2335-2348, 2016 | 1552 | 2016 |
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded … A Blauvelt, M de Bruin-Weller, M Gooderham, JC Cather, J Weisman, ... The Lancet 389 (10086), 2287-2303, 2017 | 1027 | 2017 |
Human skin Langerhans cells are targets of dengue virus infection SJL Wu, G Grouard-Vogel, W Sun, JR Mascola, E Brachtel, R Putvatana, ... Nature medicine 6 (7), 816-820, 2000 | 878 | 2000 |
Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis KB Gordon, A Blauvelt, KA Papp, RG Langley, T Luger, M Ohtsuki, ... New England Journal of Medicine 375 (4), 345-356, 2016 | 855 | 2016 |
Circulating Th17, Th22, and Th1 cells are increased in psoriasis S Kagami, HL Rizzo, JJ Lee, Y Koguchi, A Blauvelt Journal of Investigative Dermatology 130 (5), 1373-1383, 2010 | 806 | 2010 |
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe … A Blauvelt, KA Papp, CEM Griffiths, B Randazzo, Y Wasfi, YK Shen, S Li, ... Journal of the american academy of dermatology 76 (3), 405-417, 2017 | 800 | 2017 |
IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice JS Cho, EM Pietras, NC Garcia, RI Ramos, DM Farzam, HR Monroe, ... The Journal of clinical investigation 120 (5), 1762-1773, 2010 | 686 | 2010 |
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial D Thaçi, A Blauvelt, K Reich, TF Tsai, F Vanaclocha, K Kingo, M Ziv, ... Journal of the American Academy of Dermatology 73 (3), 400-409, 2015 | 619 | 2015 |
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose … D Thaci, EL Simpson, LA Beck, T Bieber, A Blauvelt, K Papp, W Soong, ... The Lancet 387 (10013), 40-52, 2016 | 583 | 2016 |
Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis EG Harper, C Guo, H Rizzo, JV Lillis, SE Kurtz, I Skorcheva, D Purdy, ... Journal of Investigative Dermatology 129 (9), 2175-2183, 2009 | 545 | 2009 |
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and … KB Gordon, B Strober, M Lebwohl, M Augustin, A Blauvelt, Y Poulin, ... The Lancet 392 (10148), 650-661, 2018 | 528 | 2018 |
Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection M Zaitseva, A Blauvelt, S Lee, CK Lapham, V Kiaus-Kovrun, H Mostowski, ... Nature medicine 3 (12), 1369-1375, 1997 | 518 | 1997 |
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials K Reich, KA Papp, A Blauvelt, SK Tyring, R Sinclair, D Thaçi, K Nograles, ... The Lancet 390 (10091), 276-288, 2017 | 483 | 2017 |
Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5 MM Lederman, RS Veazey, R Offord, DE Mosier, J Dufour, M Mefford, ... Science 306 (5695), 485-487, 2004 | 476 | 2004 |
Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis KA Papp, A Blauvelt, M Bukhalo, M Gooderham, JG Krueger, JP Lacour, ... New England Journal of Medicine 376 (16), 1551-1560, 2017 | 471 | 2017 |
The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis A Blauvelt, A Chiricozzi Clinical reviews in allergy & immunology 55, 379-390, 2018 | 470 | 2018 |
Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines E Fitch, E Harper, I Skorcheva, SE Kurtz, A Blauvelt Current rheumatology reports 9 (6), 461-467, 2007 | 460 | 2007 |
A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis KA Papp, K Reich, C Paul, A Blauvelt, W Baran, C Bolduc, D Toth, ... British Journal of Dermatology 175 (2), 273-286, 2016 | 438 | 2016 |
Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells RE Hunger, PA Sieling, MT Ochoa, M Sugaya, AE Burdick, TH Rea, ... The Journal of clinical investigation 113 (5), 701-708, 2004 | 377 | 2004 |
Quantifying the harmful effect of psoriasis on health-related quality of life SC Weiss, AB Kimball, DJ Liewehr, A Blauvelt, ML Turner, EJ Emanuel Journal of the American Academy of Dermatology 47 (4), 512-518, 2002 | 363 | 2002 |